Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer

Cancer
Bruce E Hillner

Abstract

Women who have estrogen receptor (ER)-positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC ('Arimidex, Tamoxifen Alone or in Combination') randomized trial indicate that anastrozole significantly reduces breast cancer recurrence rates but does not provide any advantage in terms of survival at 4 years posttreatment. Furthermore, anastrozole and tamoxifen were found to have different toxicity profiles. The goals of the current study were to estimate the disease-free survival (DFS) rates and potential survival benefits associated with anastrozole use and to determine whether the incremental cost-effectiveness (ICE) was low enough to warrant an immediate switch to the use of this agent, as the long-term conclusions of the ATAC trial will not be available for several years. A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years. Daily recurrence risks, as well as the relative risks associated with various treatment-related events, were calculated using data from the ATAC trial. Study...Continue Reading

References

Jan 1, 1983·Medical Decision Making : an International Journal of the Society for Medical Decision Making·J R Beck, S G Pauker
Jan 1, 1997·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·N F RayL J Melton
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A HaymanJ C Weeks
Sep 29, 1999·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C E De LaetH A Pols
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A HaymanJ C Weeks
Mar 27, 2001·Journal of Women's Health & Gender-based Medicine·A Goodman, K Houck
May 5, 2001·Breast Cancer Research and Treatment·E S WaiI A Olivotto
Jun 26, 2001·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M E WiktorowiczE Papadimitropoulos
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GoldhirschH J Senn
Mar 1, 2002·The New England Journal of Medicine·Ian R ReidPierre J Meunier
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason H LeeLawrence J Solin
Jul 5, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·John A KanisAlan K Ogelsby
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric P WinerGeorge P Browman
Jan 15, 2003·JAMA : the Journal of the American Medical Association·Parthiv J MahadeviaNeil R Powe
Feb 6, 2003·CA: a Cancer Journal for Clinicians·Robert A SmithUNKNOWN American Cancer Society
Feb 25, 2003·Cancer·John W GamelMichael J Edwards
May 7, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric P WinerGeorge P Browman
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
Sep 10, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce E HillnerUNKNOWN American Society of Clinical Oncology
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Sep 7, 2004·Clinical Breast Cancer·Aman U Buzdar

❮ Previous
Next ❯

Citations

Dec 21, 2010·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J M NeunerA B Nattinger
Apr 6, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A Rocchi, S Verma
Jul 3, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Jonathan KarnonVicki Barghout
Mar 31, 2010·Breast Cancer Research and Treatment·Sekwon JangNavneet S Majhail
Jan 25, 2006·The Breast Journal·Alexandru EniuUNKNOWN Global Summit Treatment and Allocation of Resources Panel
Jun 9, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J M GilF Canorea
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Lesley-Ann N MillerGerald M Higa
Jan 30, 2007·Current Medical Research and Opinion·Matthew J Ellis, Caron E Rigden
Oct 1, 2011·The Lancet Oncology·Richard SullivanMatti Aapro
Nov 10, 2005·Clinical Breast Cancer·Anthony Howell, Gershon Y Locker
Jul 3, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Per E Lønning, Jürgen Geisler
Feb 20, 2007·Lancet·Francesco Boccardo, Alessandra Rubagotti
Dec 13, 2005·Critical Reviews in Oncology/hematology·Jürgen Geisler, Per E Lønning
Sep 27, 2005·The Breast : Official Journal of the European Society of Mastology·Reinhold Kilian, Franz Porzsolt
Jan 24, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Gerardus W J FrederixJan H M Schellens
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Beth WoodsNeil Hawkins
Oct 13, 2005·Expert Opinion on Pharmacotherapy·Nan Soon Wong, Kathleen I Pritchard
Sep 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David ThompsonMilton C Weinstein
Apr 3, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael E StokesCraig C Earle
Aug 31, 2016·Breast Cancer Research and Treatment·Virginie NerichBernhard Holzner
Feb 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicola Lucio LiberatoGiovanni Barosi
Apr 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeanne S MandelblattPatricia A Ganz
Jan 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A Grusenmeyer, Yu-Ning Wong
Sep 1, 2007·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Jonathan KarnonRon Akehurst
Sep 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Jonathan Karnon
Oct 15, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Sun-Kyeong ParkChanhyun Park
Nov 18, 2006·The Oncologist·Edith A Perez
Dec 3, 2008·Expert Review of Anticancer Therapy·Sarah J Needleman, Jeffrey S Tobias
Nov 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YounisC Skedgel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved